2021 Virtual AMCP

Share on: 
April 12 to April 16, 2021

Research coauthored by RTI Health Solutions researchers will be presented at the 2021 Virtual AMCP Conference.

Budget impact of introducing neratinib for third-line treatment of human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States. Anderson S, Carrico J, Brodtkorb T-H, Lalla D, Brufsky A. Poster

Pharmacological costs for the treatment of eosinophilic esophagitis in the USA. Davis AE, Jiang J, Talbird SE, Turpin R, Mellott CE, Boules M, Wojtowicz AM, Fan T. Poster 

Model structure considerations for cost-effectiveness evaluation of C3 inhibitor pegcetacoplan vs. C5 inhibitor in patients with paroxysmal nocturnal hemoglobinuria. Hillman P, Jia X, Knight C, Sarda SP, Mody-Patel N, Intorcia M, Dingli DJ. Poster 

Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HER2-overexpressed/amplified HR+ breast cancer who initiated neratinib within 1 year of completing trastuzumab in the US. Brodtkorb T-H, McDade C, Lalla D, Holmes FA.

 Direct and indirect costs of intravenous infusions of edaravone among patients with amyotrophic lateral sclerosis. Ronquest NA, Lucas A, Ciepielewska M, Miles L, Paret K, Hagan M. Poster 

Related Services:
Conference participants: